Breaking News

Sirona Biochem, Wanbang Bio Enter SGLT2 Inhibitor Agreement

By Kristin Brooks | January 27, 2014

Wanbang gains an exclusive license to anti-diabetic treatment in China

Sirona Biochem Corp. has entered an agreement with Wanbang Biopharmaceuticals, providing Wanbang an exclusive license to develop and commercialize its anti-diabetic SGLT2 inhibitor in the People's Republic of China. Sirona will receive upfront and milestone payments of as much as $9.5 million, as well as royalties on sales.
 
Wanbang will be responsible for all funding, clinical development, regulatory requirements, manufacturing, sales and marketing of the SGLT2 inhibitor in China, and will share all data generated from its clinical studies, increasing the value of Sirona's SGLT2 inhibitor for licensing in the rest of the world.
 
"We are proud to work with Wanbang Biopharma in the continued development of our SGLT2 inhibitor as treatment for this global epidemic," said Neil Belenkie, chief executive officer of Sirona Biochem.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important